Demo
LABP Nasdaq· Landos Biopharma Inc.
FundamentalsNews digest Peer analysis
Login
LABP Nasdaq· Landos Biopharma Inc.
Earnings report Q3 2023

Landos Biopharma Reports Decreased Revenue in Latest Quarter

Segments of revenue

Landos Biopharma reported a decrease in revenue for the latest quarter. The company did not provide a specific breakdown of revenue by segment in the given context.

Strengths

Despite the decrease in revenue, Landos Biopharma demonstrated strengths in managing its operating expenses. The company's research and development expenses decreased from $4.9 million in the previous year to $3.1 million in the latest quarter. This reduction can be attributed to the wind down of certain programs and decreased clinical trial costs. Additionally, Landos Biopharma saw decreases in consulting costs and depreciation expenses, further contributing to the management of operating expenses.

Challenges

The decrease in revenue indicates a weakness in Landos Biopharma's performance in the latest quarter. The company reported a net loss of $5.9 million, compared to a net loss of $7.9 million in the same quarter of the previous year. This suggests that the company may be facing challenges in generating sufficient revenue to cover its expenses and achieve profitability.

Noteworthy

It is worth noting that Landos Biopharma did not provide a specific breakdown of revenue by segment in the given context. Therefore, it is difficult to assess the performance of individual segments and identify any noteworthy trends or developments.

Summary

Landos Biopharma reported a decrease in revenue in the latest quarter, resulting in a net loss of $5.9 million. The company demonstrated strengths in managing its operating expenses, with a decrease in research and development expenses. However, the decrease in revenue indicates a weakness in the company's performance. Further analysis is required to assess the performance of individual segments and identify any significant trends or developments.

Source documents

Form 10-Q  filed on Nov 09, 2023
12 pages scanned

Reference data

Company financials Q3 revenue 0
Analyst estimates Q3 EPS missed by NaN%
Sign up to Fey

Get in-depth analysis on thousands of stocks for just $30/month. Cancel anytime.